ATNM Actinium Pharmaceuticals, Inc.
$1.41▲ +0.80%
Healthcare
Other
Volume 51.3K
Avg Volume (10D) 368.1K
Key Metrics & Fundamentals
Market Cap
$44.37M
P/E Ratio
4.3
Div Yield
0.00%
52W Range
0.74 - 1.72
% vs 50 MA
20.32%
% vs 200 MA
25.23%
RSI-14
59.7
MACD Histogram
+0.0400
Beta (1Y vs SPY)
0.43
Free Cash Flow
-$5.66M
Gross Rev
$35.00M
Gross Profit
$35.00M
EBITDA
$27.81M
COGS
–
Operating Exp
$7.44M
Operating Income
$27.57M
EBIT
$27.57M
Pretax Income
$27.90M
Net Income
$27.90M
EPS (Diluted)
0.89
Price & Volume History
Loading chart…
Recent News
Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026
PR Newswire · Oct 23, 2026 8:00 AM ET
Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer
PR Newswire · Oct 20, 2026 8:00 AM ET
Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models
PR Newswire · Oct 20, 2026 7:30 AM ET
Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026
PR Newswire · Oct 19, 2026 7:30 AM ET
Actinium Pharmaceuticals Announces Inducement Grants to New Employees
PR Newswire · Oct 16, 2026 5:00 PM ET
ATNM: Introduction to Radiopharmaceuticals
Zacks Small Cap Research · Oct 16, 2026 12:02 PM ET
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models
PR Newswire · Oct 16, 2026 8:30 AM ET
Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development
PR Newswire · Oct 16, 2026 7:30 AM ET
Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer
PR Newswire · Oct 15, 2026 8:30 AM ET
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
PR Newswire · Oct 15, 2026 7:30 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ATNM's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.